Dimethyl fumarate prevents acute lung injury related cognitive impairment potentially via reducing inflammation

Xiaowei Wang1, Yanbo Wang2, Haiyan Pan3

  • 1Department of Respiratory, The Third Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou City, 310000, Zhejiang Province, China.

Abstract

Insights

Dimethyl fumarate (DMF) treatment alleviated acute lung injury (ALI) and associated cognitive impairment in a mouse model. This protective effect was linked to reduced inflammation and improved brain function.

Area of Science:

  • Pulmonary Medicine
  • Neuroscience
  • Pharmacology

Background:

  • Dimethyl fumarate (DMF) shows promise in treating lung and cognitive diseases.
  • Acute Lung Injury (ALI) can lead to systemic inflammation and cognitive deficits.

Purpose of the Study:

  • To investigate the protective effects of DMF on ALI and related cognitive impairment in a mouse model.
  • To explore the underlying mechanisms of DMF's action.

Main Methods:

  • An ALI mouse model was induced using lipopolysaccharide (LPS).
  • Mice were treated with DMF or a placebo.
  • Cognitive function was assessed using the Morris water maze test.
  • Lung injury markers, brain edema, blood-brain barrier (BBB) permeability, and inflammatory factors were analyzed.

Main Results:

  • DMF significantly reduced inflammatory cell counts and protein levels in bronchoalveolar lavage fluid (BALF).
  • DMF suppressed key inflammatory cytokines (IL-6, TNF-α, IL-1β) in BALF, serum, and brain tissue.
  • DMF treatment improved cognitive performance in ALI mice, reducing escape latency and path length.
  • DMF mitigated BBB permeability and brain edema.
  • DMF downregulated HIF-1α expression in lung and brain tissues.

Conclusions:

  • Dimethyl fumarate (DMF) demonstrates significant therapeutic potential for mitigating acute lung injury (ALI) and associated cognitive impairment.
  • DMF's protective effects are partly attributed to its anti-inflammatory properties.
  • Further research into DMF as a treatment for ALI-induced cognitive dysfunction is warranted.

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
235
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
708
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
671
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
232